Table 2.
Desensitisation protocol and outcome
| Patient 1 | Patient 2 | Patient 3 | |
| Before desensitization with original donor | |||
| LCM/DTT/AHG (%) | 80/80/90 | 5/5/7 | 5/0/5 |
| T/B FCM (MCS) | 260/298 | Neg/236 | 80/159 |
| DSA class 1 | A1 = 8000, B57 = 6200 | No DSA | B44 = 4188, A31 1100 |
| DSA class 2 | DQ7 = 1600, DQ9 = 2200 | DQ2 = 9000 | No DSA |
| DP | 8TPE + 8Bort/MP/IVIG + TAC/MMF | 9TPE + 6Bort/MP/IVIG + R + TAC/MMF | 4TPE + 4Bort/MP/IVIG + TAC/MMF |
| After desensitization with original donor | |||
| LCM | 80/80/90 | 17/15/20 | 5/0/7 |
| FCM | 254/333 | Neg/504 | Neg/129 |
| DSA class 1 | A1 = 2000, B57 = 5500 | No DSA | B44 = 4622, A31 = 1400 |
| DSA class 2 | DQ7 = 2000, DQ9 = 2000 | DQ2 = 12000 | No DSA |
| Side effects | Tuberculosis | Graft nephrectomy | Tuberculosis |
TPE: Plasmapheresis; Bort: Bortezomib; MP: Methyl prednisolone; IVIG: Immunoglobulin; R: Rituximab; TAC: Tacrolimus; MMF: Mycophenolate mofetyl; DP: Desensitization protocol; LCM: Lymphocyte cross match; FCM: Flow cross match; DSA: Donor specific antibody; Neg: Negative; MCS: Median channel shift; DTT: Dithiothreitol; AHG: Antihuman globulin test.